Response to the Letter to the Editor: Rare Endocrine Disorders and Peripheral Arterial Disease

Mojca Jensterle; Ales Blinc; Dimitri P Mikhailidis; Panagiotis Anagnostis; Gerit-Holger Schernthaner; Pier Luigi Antignani; Katica Bajuk Studen; Miso Šabović; Pavel Poredoš

doi:10.2174/0115701611372375241125111238

ISSN: 1570-1611
E-ISSN: 1875-6212

HTML

f Response to the Letter to the Editor: Rare Endocrine Disorders and Peripheral Arterial Disease
Authors: Mojca Jensterle^1,2, Ales Blinc^2,3, Dimitri P Mikhailidis⁴, Panagiotis Anagnostis⁵, Gerit-Holger Schernthaner⁶, Pier Luigi Antignani⁷, Katica Bajuk Studen^2,8, Miso Šabović^2,3 and Pavel Poredoš^2,3
View Affiliations Hide Affiliations

¹ Department of Endocrinology, Diabetes and Metabolic Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia ; ² Faculty of Medicine, Department of Internal Medicine, University of Ljubljana, Ljubljana, Slovenia ; ³ Department of Vascular Diseases, University Medical Centre Ljubljana, Ljubljana, Slovenia ; ⁴ Department of Surgical Biotechnology, Division of Surgery and Interventional Science, University College London Medical School, University College London; ⁵ Unit of Reproductive Endocrinology, 1st Department of Obstetrics and Gynecology, Medical School, Aristotle University of Thessaloniki, Thessaloniki, Greece ; ⁶ Department of Medicine 2, Division of Angiology, Medical University of Vienna, Vienna, Austria ; ⁷ Vascular Centre Nuova Villa Claudia, Rome, Italy ; ⁸ Department of Nuclear Medicine, University Medical Centre, Ljubljana, Slovenia
Source: Current Vascular Pharmacology, Volume 23, Issue 1, Jan 2025, p. 9 - 11
DOI: https://doi.org/10.2174/0115701611372375241125111238
- Received: 19 Nov 2024
- Accepted: 20 Nov 2024
- Available online: 04 Dec 2024

Preview this article:

There is no abstract available.

Article metrics loading...

/content/journals/cvp/10.2174/0115701611372375241125111238

2024-12-04

2025-07-23

From This Site

/content/journals/cvp/10.2174/0115701611372375241125111238

dcterms_title,dcterms_subject,pub_keyword

-contentType:Contributor -contentType:Concept -contentType:Institution

10

5

Full text loading...

/deliver/fulltext/cvp/23/1/CVP-23-1-04.html?itemId=/content/journals/cvp/10.2174/0115701611372375241125111238&mimeType=html&fmt=ahah

References

PoredošP. SchernthanerG.H. BlincA. MikhailidisD.P. AntignaniP.L. AnagnostisP.G. JensterleM. StudenK.B. ŠabovićM. JezovnikM.K. Endocrine disorders and peripheral arterial disease: A series of reviews.Curr. Vasc. Pharmacol.202321314714810.2174/157016112166623051614131937194233
[Google Scholar]
BlincA. SchernthanerG.H. PoredošP. AnagnostisP. JensterleM. StudenK.B. AntignaniP.L. MikhailidisD.P. ŠabovićM. Testosterone and peripheral arterial disease.Curr. Vasc. Pharmacol.202321529730310.2174/157016112166623080914302337559242
[Google Scholar]
AnagnostisP. MikhailidisD.P. BlincA. JensterleM. JežovnikM.K. SchernthanerG.H. AntignaniP.L. StudenK.B. ŠabovićM. PoredosP. The effect of menopause and menopausal hormone therapy on the risk of peripheral artery disease.Curr. Vasc. Pharmacol.202321529329610.2174/011570161126334523091912290737779405
[Google Scholar]
JanezA. HermanR. PoredosP. MikhailidisD.P. BlincA. SabovicM. StudenK.B. JezovnikM.K. SchernthanerG.H. AnagnostisP. AntignaniP.L. JensterleM. Cardiometabolic risk, peripheral arterial disease and cardiovascular events in polycystic ovary syndrome: Time to implement systematic screening and update the management.Curr. Vasc. Pharmacol.202321642443210.2174/011570161126914623092007330137779406
[Google Scholar]
StudenK.B. GaberscekS. ZaletelK. BlincA. SabovicM. SchernthanerG.H. AnagnostisP. AntignaniP.L. JensterleM. MikhailidisD.P. PoredosP. Thyroid disorders and peripheral arterial disease.Curr. Vasc. Pharmacol.2024221364010.2174/011570161127128423110506314837957913
[Google Scholar]
RH. AJ. DpM. PP. AB. MS. KB.S. GhS. PA. PlA. MJ. Growth hormone, atherosclerosis and peripheral arterial disease: Exploring the spectrum from acromegaly to growth hormone deficiency.Curr. Vasc. Pharmacol.2024221283510.2174/011570161126916223110604295637962050
[Google Scholar]
PP. GhS. AB. DpM. MJ. PA. PlA. KB.S. MŠ. MkJ. Endocrine disorders and peripheral arterial disease – A series of reviews Cushing syndrome-cortisol excess.Curr. Vasc. Pharmacol.202422423624110.2174/011570161127214523110605391438038006
[Google Scholar]
AntignaniP.L. JezovnikM.K. BlincA. MikhailidisD.P. AnagnostisP. SchernthanerG.H. JensterleM. StudenK.B. SabovicM. PoredosP. Hyperparathyroidism and peripheral arterial disease.Curr. Vasc. Pharmacol.2024222889410.2174/011570161128090523122704582638284694
[Google Scholar]
PapaioannouV. TsiantoulaP. Rare endocrine disorders and peripheral arterial disease.Curr Vasc Pharmacol2024
[Google Scholar]
NgaosuwanK. JohnstonD. GodslandI. Cardiovascular disease in patients with primary and secondary adrenal insufficiency and the role of comorbidities.J Clin Endocrinol Metab202110651284129310.1210/clinem/dgab063
[Google Scholar]
ZhaoR. LuoS. WangS. WenY. XiongF. Coronary artery disease in a patient with Addison’s disease: A case report and literature review.BMC Cardiovasc. Disord.20232315410.1186/s12872‑023‑03079‑036709280
[Google Scholar]
GuarnottaV. Di StefanoC. TomaselloL. ManiscalcoL. PizzolantiG. ArnaldiG. GiordanoC. Conventional steroids vs. dual-release hydrocortisone on metabolic, cardiovascular, and bone outcomes in adrenal insufficiency: A 10-year study.Eur. J. Endocrinol.2024191330031110.1093/ejendo/lvae10739171906
[Google Scholar]
NtaliG. MarkussisV. ChrisoulidouA. An overview of cardiovascular risk in pituitary disorders.Medicina2024608124110.3390/medicina6008124139202522
[Google Scholar]
MastnakL. HermanR. FerjanS. JanežA. JensterleM. Prolactin in polycystic ovary syndrome: Metabolic effects and therapeutic prospects.Life20231311212410.3390/life1311212438004264
[Google Scholar]
FeldmanR.D. SanjanwalaR. PadwalR. LeungA.A. Revising the roles of aldosterone in vascular physiology and pathophysiology: From electocortin to baxdrostat.Can. J. Cardiol.202339121808181510.1016/j.cjca.2023.08.03537734710
[Google Scholar]
PetramalaL. ConcistrèA. MezzadriM. SarloF. CircostaF. SchinaM. SoldiniM. IannucciG. LetiziaC. Relationship between plasma aldosterone levels and arterial stiffness parameters in hypertensive patients with subclinical vascular damage.Int. J. Cardiol. Cardiovasc. Risk Prev.20221420013810.1016/j.ijcrp.2022.20013836060288
[Google Scholar]

/content/journals/cvp/10.2174/0115701611372375241125111238

Article Type: Editorial

f Response to the Letter to the Editor: Rare Endocrine Disorders and Peripheral Arterial Disease

From This Site

Most Read This Month

Most Cited Most Cited RSS feed

Endothelin-1-Induced Signaling Pathways in Vascular Smooth Muscle Cells

Optical Techniques in the Assessment of Peripheral Arterial Disease

Equilibrative Nucleoside (ENTs) and Cationic Amino Acid (CATs) Transporters: Implications in Foetal Endothelial Dysfunction in Human Pregnancy Diseases

Use of BNP and CRP as Biomarkers in Assessing Cardiovascular Disease:Diagnosis Versus Risk

The Significance of Endothelium-Derived Hyperpolarizing Factor in the Human Circulation

Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells

Vascular Disease: A New Progenitor Biology

Burden of Ischemic Heart Diseases among US States from 1990-2019

Prognostic Value of Serum TMAO Measurement in Patients with STEMI: A Systematic Literature Review

Emotional Stress in Cardiac and Vascular Diseases